ONCOLYTICS BIOTECH INC (ONCY) Stock Price & Overview

NASDAQ:ONCY • CA6823108759

0.9615 USD
-0.05 (-4.8%)
At close: Mar 12, 2026
0.97 USD
+0.01 (+0.88%)
After Hours: 3/12/2026, 8:00:02 PM

The current stock price of ONCY is 0.9615 USD. Today ONCY is down by -4.8%. In the past month the price increased by 12.65%. In the past year, price increased by 53.84%.

ONCY Key Statistics

52-Week Range0.3258 - 1.51
Current ONCY stock price positioned within its 52-week range.
1-Month Range0.819 - 1.19
Current ONCY stock price positioned within its 1-month range.
Market Cap
103.467M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.29
Dividend Yield
N/A

ONCY Stock Performance

Today
-4.8%
1 Week
-8.43%
1 Month
+12.65%
3 Months
-3.18%
Longer-term
6 Months -24.88%
1 Year +53.84%
2 Years -9.29%
3 Years -19.88%
5 Years -74.76%
10 Years N/A

ONCY Stock Chart

ONCOLYTICS BIOTECH INC / ONCY Daily stock chart

ONCY Technical Analysis

ChartMill assigns a technical rating of 5 / 10 to ONCY. When comparing the yearly performance of all stocks, ONCY is one of the better performing stocks in the market, outperforming 85.56% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating
ONCY Full Technical Analysis Report

ONCY Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to ONCY. ONCY has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
ONCY Full Fundamental Analysis Report

ONCY Earnings

Next Earnings DateMay 12, 2026
Last Earnings DateMar 5, 2026
PeriodQ3 / 2025
EPS Reported-CA$0.14
Revenue Reported
EPS Surprise -43.48%
Revenue Surprise %
ONCY Earnings History

ONCY Forecast & Estimates

8 analysts have analysed ONCY and the average price target is 3.32 USD. This implies a price increase of 245.23% is expected in the next year compared to the current price of 0.9615.


Analysts
Analysts77.5
Price Target3.32 (245.29%)
EPS Next Y21.99%
Revenue Next YearN/A
ONCY Forecast & Estimates

ONCY Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

ONCY Financial Highlights

Over the last trailing twelve months ONCY reported a non-GAAP Earnings per Share(EPS) of -0.29. The EPS decreased by -8.36% compared to the year before.


Income Statements
Revenue(TTM)N/A
Net Income(TTM)-30.41M
Industry RankSector Rank
PM (TTM) N/A
ROA -152.26%
ROE -499.46%
Debt/Equity 0.1
Chartmill High Growth Momentum
EPS Q2Q%-16.74%
Sales Q2Q%N/A
EPS 1Y (TTM)-8.36%
Revenue 1Y (TTM)N/A
ONCY financials

ONCY Ownership

Ownership
Inst Owners2.6%
Shares107.61M
Float103.72M
Ins Owners3.49%
Short Float %6.94%
Short Ratio5.13
ONCY Ownership

ONCY Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
SymbolCompany NameTechnical RatingFundamental RatingFPEMarket Cap
ABBV ABBVIE INC15.19402.577B
AMGN AMGEN INC16.11203.574B
GILD GILEAD SCIENCES INC16.43181.247B
VRTX VERTEX PHARMACEUTICALS INC24.66125.079B
REGN REGENERON PHARMACEUTICALS15.9781.897B
ALNY ALNYLAM PHARMACEUTICALS INC42.5242.495B
INSM INSMED INC N/A30.048B
BIIB BIOGEN INC11.527.955B
NTRA NATERA INC N/A27.865B
UTHR UNITED THERAPEUTICS CORP17.8423.875B
MRNA MODERNA INC N/A22.105B
EXAS EXACT SCIENCES CORP339.7519.738B
RVMD REVOLUTION MEDICINES INC N/A19.736B

About ONCY

Company Profile

ONCY logo image Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-05. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Company Info

IPO: 2001-10-05

ONCOLYTICS BIOTECH INC

804, 322 - 11 Avenue Sw, Calgary Alberta Canada T2n 1X7

Calgary ALBERTA T2N 1X7 CA

CEO: Matthew C. Coffey

Employees: 29

ONCY Company Website

ONCY Investor Relations

Phone: 14036707377

ONCOLYTICS BIOTECH INC / ONCY FAQ

What does ONCOLYTICS BIOTECH INC do?

Oncolytics Biotech, Inc. engages in the provision of development of immuno-oncolytic virus for the treatment of solid tumors and hematological malignancies. The company is headquartered in Calgary, Alberta. The company went IPO on 2001-10-05. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The company acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The firm is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


What is the stock price of ONCOLYTICS BIOTECH INC today?

The current stock price of ONCY is 0.9615 USD. The price decreased by -4.8% in the last trading session.


Does ONCOLYTICS BIOTECH INC pay dividends?

ONCY does not pay a dividend.


What is the ChartMill rating of ONCOLYTICS BIOTECH INC stock?

ONCY has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 1 out of 10.


What sector and industry does ONCOLYTICS BIOTECH INC belong to?

ONCOLYTICS BIOTECH INC (ONCY) operates in the Health Care sector and the Biotechnology industry.


What is the employee count for ONCY stock?

ONCOLYTICS BIOTECH INC (ONCY) currently has 29 employees.


What is ONCOLYTICS BIOTECH INC worth?

ONCOLYTICS BIOTECH INC (ONCY) has a market capitalization of 103.47M USD. This makes ONCY a Micro Cap stock.